Drug intelligence / Profile preview

LY4064912

Development stage: Phase 1
Lead developer: Eli Lilly
Modality: Small Molecules
Administration: Subcutaneous, Intravenous

Overview

LY4064912 is an investigational small molecule drug developed by Eli Lilly and Company for the treatment of overweight and obesity. It is currently being evaluated to determine its safety, tolerability, and pharmacokinetic properties in both healthy individuals and those with overweight or obesity. The drug is administered either subcutaneously or intravenously. Mechanism of action and molecular target have not been publicly disclosed as of the available clinical trial records[1][3].

Beyond the preview

Go deeper on LY4064912.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LY4064912.

Explore the full profile